about
Determinants of Glycosaminoglycan (GAG) StructureControl of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene familyDentin Sialophophoprotein (DSPP) and Dentin.Dentinogenesis and Dentin Sialophosphoprotein (DSPP)Porcine dentin sialoprotein glycosylation and glycosaminoglycan attachmentsBlood cells transcriptomics as source of potential biomarkers of articular health improvement: effects of oral intake of a rooster combs extract rich in hyaluronic acidSpondyloocular Syndrome: Novel Mutations in XYLT2 Gene and Expansion of the Phenotypic Spectrum.Breast cancer: coordinated regulation of CCL2 secretion by intracellular glycosaminoglycans and chemokine motifs.Transforming growth factor beta1-regulated xylosyltransferase I activity in human cardiac fibroblasts and its impact for myocardial remodeling.A novel function of heparan sulfate in the regulation of cell-cell fusion.Serum xylosyltransferase activity in diabetic patients as a possible marker of reduced proteoglycan biosynthesis.Xylosyltransferase II is a significant contributor of circulating xylosyltransferase levels and platelets constitute an important source of xylosyltransferase in serum.XYLT1 mutations in Desbuquois dysplasia type 2.Rare and unusual glycosylation of peptides and proteins.Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.Identification and characterization of the human xylosyltransferase I gene promoter region.Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans.Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte maturation and skeletal length.New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers.Regulation of xylosyltransferase I gene expression by interleukin 1β in human primary chondrocyte cells: mechanism and impact on proteoglycan synthesis.The missing "link": an autosomal recessive short stature syndrome caused by a hypofunctional XYLT1 mutation.Virulence Factors as Targets for Anticryptococcal Therapy.Desbuquois dysplasia type II in a patient with a homozygous mutation in XYLT1 and new unusual findings.
P2860
Q26797302-454CA41D-CA81-46C2-984F-3B75F1BDC1F7Q26864268-2024EAD2-FEC0-4F1E-B23E-80C00A612947Q33555689-34E8612F-E20D-4D41-A2E2-2DBCC52F80CBQ33649653-FD12A8A8-3CD0-4560-815E-B0F51DBB5D20Q33811338-951E2915-7437-4FDE-A57E-FEF7A164BC0BQ34232764-3EB4472F-207F-4D73-A739-9B4B7DA8667EQ34518676-DE5A8965-3DBC-489E-B86D-8846CEEE5081Q34528303-B46AC73E-433C-4AFD-9A2E-627654FB1905Q34652219-C477CA51-E77B-4654-A782-E33266DF8A62Q35000955-CC126954-54E4-4E3D-85C1-5BFDFED7F9DFQ36906253-79BCDD62-3814-4026-8891-B5F4E9D68893Q37248241-C1CCA0B6-8E3C-4697-9C6B-1739925C154FQ37634126-D1E8DBBC-EF5B-4983-AA8A-845763249B18Q38003341-12DFCFEC-D326-4662-911D-DCD1911769F9Q39060517-17CD30B5-D27B-41B1-8FE6-BD6F1925938EQ39798204-4891AA52-46AE-46BA-8427-1FB7741481D2Q41512598-005AA0AD-844B-4389-8396-D3DA0B5F0A54Q41879476-77BFAAA2-985F-436F-A79F-5D382F2C4446Q42164144-D76120AF-645D-486E-9160-4C96451BA232Q42798764-9A61D89E-9ECE-4878-BD03-8D9DD48B1ADCQ47686477-965CF88B-2150-4110-A504-7D953FF530BEQ49612928-8D294216-D84F-4DAA-B4A3-414A8111C282Q53058359-925FC0B1-4923-40D6-8B47-F74CA6CA4BEE
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Human xylosyltransferases in health and disease.
@ast
Human xylosyltransferases in health and disease.
@en
type
label
Human xylosyltransferases in health and disease.
@ast
Human xylosyltransferases in health and disease.
@en
prefLabel
Human xylosyltransferases in health and disease.
@ast
Human xylosyltransferases in health and disease.
@en
P2093
P1476
Human xylosyltransferases in health and disease.
@en
P2093
P2888
P304
P356
10.1007/S00018-007-7069-Z
P577
2007-06-01T00:00:00Z